Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors
Background/Aim: Advanced melanoma treatment remains debated, particularly in patients with B-Raf proto-oncogene serine/threonine kinase (BRAF) V600 mutations eligible for both immune checkpoint inhibitors (ICI) and BRAF/MEK inhibitors. Additional biomarkers are needed to improve treatment selection. Mutations of the te...